Professional Documents
Culture Documents
Psoriasis-Tto bg2005
Psoriasis-Tto bg2005
CRÓNICA EN
PLACAS
Eligibility criteria
To be considered eligible for treatment, patients must have severe disease as defined in (a) and fulfil one of
the clinical categories outlined in (b):
(a)Severe disease is defined as a PASI score of 10 or more (or a BSA of 10% or greater
where PASI is not applicable) and a DLQI>10.
Disease should have been severe for 6 months, resistant to treatment and the patient should be a candidate for
systemic therapy.
In exceptional circumstances (for example, disabling acral disease), patients with severe disease may fall outside
this definition but may be considered for treatment. (Strength of recommendation, level of evidence 3).
AND
(b) fulfil at least one of the following clinical categories (Strength of recommendation B, level of
evidence 1++ and formal consensus):
(i) have developed or are at higher than average risk of developing clinically important drug-related toxicity
and where alternative standard therapy a cannot be used
(ii) are or have become intolerant to or cannot receive standard systemic therapy
(iii) are or have become unresponsive to standard therapy
(iv) have disease that is only controlled by repeated inpatient management
(v) have significant, coexistent, unrelated comorbidity which precludes use of systemic agents such as
ciclosporin or methotrexate
(vi) have severe, unstable, life-threatening disease (erythrodermic or pustular psoriasis)
(vii) have psoriatic arthritis fulfilling the British Society for Rheumatology (BSR) eligibility criteria for treatment
with anti-TNF agents,11 in association with skin disease
66%
88%
35% 50%
31%
46%
31%
22%
Menor riesgo
- En monoterapia
- Con Etanercept: solo 9 casos reportados a la FDA.
Tiempo desde inicio de Infliximab hasta diagnóstico
de TBC
Braun et al Tuberculosis associated with Infliximab. NEJM
2001
PROFILAXIS TBC.
PAUTAS DE ACTUACIÓN EN TBC ANTES DE INICIAR TRATAMIENTO ANTI-TNF
C.H. Smith et al. Biological interventions for Psoriasis British Jounal of Dermatology 2005.
Otras reacciones adversas menos frecuentes
pero más graves (I)
ENFERMEDADES CARDIOVASCULARES
- Evitar si Insuficiencia cardíaca grado III-IV NYHA
- En grado I-II valorar muy bien la relación B-R.
NEOPLASIAS
ENFERMEDADES NEUROLÓGICAS
HEPATITIS
- 35 casos con Infliximab. (notificación espontánea)
- Buena tolerancia.
TROMBOCITOPENIA
- 1/500-1000 pacientes. Monitorización del recuento plaquetario.
REBROTES DE PSORIASIS
-Más frecuente en no respondedores y después de la suspensión.
- Embarazo o lactancia.
- Infecciones activas.
- Contraindicaciones relativas:
- PUVA (más de 200 ciclos)
- VIH o SIDA.
- VHC o VHB
PAUTAS RECOMENDADAS ANTES DE INICIAR EL
TRATAMIENTO
- Exploración dermatológica (PASI y DLQI): antes, a los 3 meses y después cada 6 meses.
Adaptado de C.H. Smith et al. Biological interventions for Psoriasis BJD 2005.
¿ DEBEN TRATARSE
TODOS LOS PACIENTES
CON TRATAMIENTOS BIOLÓGICOS?
Indicaciones. Beneficio/ riesgo
PASI Y PASI%
CALCULO DE LOS COSTES
15 mg/wk 24 71.6
PUV-A* + acitretin Lauharanta† Acitretin 40 mg/d for 2 wk, then acitretin 20 mg/d + PUV-A 3×/wk for 8 wk 34 97.3
PUV-A[86] 4×/wk for 6 wk, then 2×/wk for 2 1×/wk for 44 wk $3737
wk[55]
3×/wk for 10 wk[56] 1×/wk for 42 wk $3737
Acitretin 48.2 mg/d[57] Constant daily dose (two 25-mg tablets) $12,359
Cyclosporine 3 mg/kg/d[58] Constant daily dose (two 100-mg and one 25-mg tablets) $5019
1.5 mg/kg/d[59] Constant daily dose (one 100-mg and one 25-mg tablets) $2789
Efalizumab 1 mg/kg/wk[24] Constant dose (75 mg/wk, requiring 1 vial with 50 mg of $17,836
waste)
Etanercept 50 mg 2×/wk for 12 wk[62] 25 mg 2×/wk for 40 wk (1 vial contains 25 mg) $21,052
Infliximab 5 mg/kg at wk 0, 2, and 6[63] 375 mg every 8 wk for 46 wk (6 administrations), requiring $24,898
4 vials with 25 mg of waste
UV-B‡ + acitretin UV-B: 5 - 7×/wk for 12 wk; acitretin: UV-B 0.5×/wk,§ acitretin reduced to 25 mg (single tablet) $3792
25 mg/d for 12 wk[64] every other day for 40 wk
PUV-A + acitretin Acitretin: 40 mg/d (one 25-mg, one PUV-A 0.5×/wk§ + acitretin reduced to 25 mg every other $6773
10-mg, and half 10-mg tablets) for 2 day for 42 wk
wk, then 20 mg/d plus PUV-A 3×/wk
for 8 wk[65]
Cost/y, Cost/y,
Treatment Rx Del Mon AE Total PASI% PASI1 PASI50 PASI75
Cyclosporine 3 mg/kg 5019 — 1794 138 6951 52.0 134 6683 10,025
Cyclosporine 1.5 mg/kg 2789 — 1794 138 4721 33.4 141 7067 10,600
Infliximab 5 mg/kg 24,898 1422 116 — 26,436 82.8 319 15,964 23,946
Tratamiento alternativo.